Reno NV 卵巢癌临床试验
7项针对 卵巢癌的研究正在 Reno及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
正在为研究招募参与者?将此页面置顶展示 — $99 / 30天 →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
招募中2 期
- Renown Regional Medical Center, Reno
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
招募中2 期
- The Center Of Hope /ID# 274313, Reno
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
招募中2 期
- Site 0213 - Center of Hope, Reno
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
招募中3 期
- The Center of Hope, Reno
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
招募中3 期
- The Center of Hope ( Site 0025), Reno
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
招募中3 期
- Center of Hope, Reno
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
招募中3 期
- Center of Hope, Reno
其他城市的 卵巢癌试验
- Houston, TX89 项研究
- New York City, NY69 项研究
- Boston, MA61 项研究
- Los Angeles, CA50 项研究
- Nashville, TN49 项研究
- Arlington, VA46 项研究
- Philadelphia, PA44 项研究
- Columbus, OH39 项研究
- St. Louis, MO38 项研究
- Chicago, IL36 项研究
- San Antonio, TX31 项研究
- Cleveland, OH30 项研究
Reno的其他研究
- 非小细胞肺癌16 项研究
- 乳腺癌13 项研究
- 肺癌9 项研究
- 黄斑变性8 项研究
- 地图样萎缩8 项研究
- 癌症(所有类型)7 项研究
- 急性髓系白血病5 项研究
- 胰腺癌5 项研究
- 转移性癌症5 项研究
- 结肠癌5 项研究
- 结直肠癌5 项研究
- 直肠癌4 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年10月6日。每项研究自行设定入选标准,由研究团队决定谁能参与。